{
    "clinical_study": {
        "@rank": "60381", 
        "acronym": "COMPHI", 
        "arm_group": {
            "arm_group_label": "Group 1"
        }, 
        "brief_summary": {
            "textblock": "This pilot, non-interventional, company-sponsored, multi-center study documents\n      observational data on patients under routine treatment of Pulmonary Arterial Hypertension\n      (PAH) with inhaled iloprost (using I-Neb device for the inhalation).\n\n      The planned study recruitment time is 18 months. The maximum follow up period in this study\n      will be 12 months.\n\n      The data will be collected from patients who have initiated the treatment mentioned above\n      (inhaled iloprost using I-Neb device) since February 1st, 2013.\n\n      Frequency of visits and procedures will be performed under routine conditions. The primary\n      objective of this study is to assess the compliance of patients with WHO/NYHA (World Health\n      Organization/New York Heart Association) functional Class III Pulmonary Arterial\n      Hypertension treated with Inhaled Iloprost in clinical practice, using the I-neb Insight\n      tool."
        }, 
        "brief_title": "Non-interventional Multi-center Study on Patients Under Routine Treatment of Pulmonary Arterial Hypertension (PAH) With Inhaled Iloprost Using I-Neb as a Device for Inhalation", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Pulmonary Hypertension", 
        "condition_browse": {
            "mesh_term": [
                "Hypertension, Pulmonary", 
                "Hypertension"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients (age \u2265 18years old), male or female\n\n          -  Diagnosis of Pulmonary Arterial Hypertension, Group I of the Dana Point Pulmonary\n             Hypertension classification (Diagnosis made at the discretion of the attending\n             investigator, including mPAP \u2265 25 mmHg at rest, as measured by right heart\n             catheterization.)\n\n          -  The treating physician has chosen to initiate the treatment with inhaled iloprost\n             with I-Neb device for the application, as described in the Summary of Product\n             characteristics (SmPC).\n\n          -  WHO/NYHA functional class III\n\n          -  Willing to participate in the study (Informed Consent Sign)\n\n          -  Patients who received the first inhaled iloprost treatment with I-Neb from February\n             1st, 2013.\n\n        Exclusion Criteria:\n\n          -  Any contraindication for the treatment with Ventavis as described in the Summary of\n             Product characteristics (SmPC)\n\n          -  Patients are not to be enrolled if they were treated with inhaled iloprost with I-Neb\n             or any other device for the application in the past, before the start of the\n             observation period (February 1st, 2013)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients Diagnosed with Pulmonary Arterial Hypertension, Functional Class NYHA/WHO III,\n        for whom the treating physician has chosen to initiate the treatment with inhaled iloprost\n        using I-Neb as the device for inhalation since 1st of February of 2013."
            }
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01894035", 
            "org_study_id": "16755", 
            "secondary_id": "VE1310PT"
        }, 
        "intervention": {
            "arm_group_label": "Group 1", 
            "description": "Patients Diagnosed with Pulmonary Arterial Hypertension, Functional Class NYHA/WHO III, for whom was prescribed inhaled Iloprost.", 
            "intervention_name": "Ventavis (Iloprost, BAYQ6256)", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Iloprost"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Pulmonary Hypertension", 
            "Ventavis", 
            "Patient compliance"
        ], 
        "lastchanged_date": "May 27, 2014", 
        "link": [
            {
                "description": "Click here and search for drug information provided by the FDA.", 
                "url": "http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm"
            }, 
            {
                "description": "Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.", 
                "url": "http://www.fda.gov/medwatch/safety.htm"
            }
        ], 
        "location": {
            "facility": {
                "address": {
                    "city": "Many Locations", 
                    "country": "Portugal"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Portugal"
        }, 
        "number_of_groups": "1", 
        "official_title": "Study to Assess the Compliance of Patients With Pulmonary Arterial Hypertension Treated With Inhaled Iloprost", 
        "overall_contact": {
            "email": "clinical-trials-contact@bayerhealthcare.com", 
            "last_name": "Bayer Clinical Trials Contact"
        }, 
        "overall_official": {
            "affiliation": "Bayer", 
            "last_name": "Bayer Study Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Portugal: Health Ethic Committee", 
                "Portugal: National Data Protection Committee"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The compliance will be assessed by the mean daily number of Inhalations and mean daily dose of Ventavis at around months 6 and 12 for each patient (Data will be collected via the I-neb Insight). For this observational study, a patient is considered compliant if the mean daily number of inhalations and mean daily dose are within 80 to 120% of prescribed. Otherwise, the patient will be considered as non-compliant.", 
            "measure": "Percentage of compliant patients", 
            "safety_issue": "No", 
            "time_frame": "Up to 12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01894035"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Observed treatment duration days", 
                "safety_issue": "No", 
                "time_frame": "Up to 12 months"
            }, 
            {
                "measure": "Expected treatment duration days", 
                "safety_issue": "No", 
                "time_frame": "Up to 12 months"
            }, 
            {
                "measure": "Changes in WHO/ NYHA Functional Class", 
                "safety_issue": "No", 
                "time_frame": "Up to 12 months"
            }, 
            {
                "measure": "Change in 6 MWDT (6 minute walking distance test) scale value", 
                "safety_issue": "No", 
                "time_frame": "Up to 12 months"
            }, 
            {
                "measure": "Change in Dyspnea Borg CR (category ratio) 10 scale value", 
                "safety_issue": "No", 
                "time_frame": "Up to 12 months"
            }, 
            {
                "measure": "Quality of life using validated scales (EuroQol questionnaire [EQ-5D], Living with Pulmonary Hypertension questionnaire [LPH])", 
                "safety_issue": "No", 
                "time_frame": "Up to 12 months"
            }
        ], 
        "source": "Bayer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bayer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}